Nephron protection in diabetic kidney disease

New England Journal of Medicine

Volumn 375, Issue 21, 2016, Pages 2096-2098

  Anders, Hans Joachim ^a   Davis, John M ^b   Thurau, Klaus ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; GLOMERULUS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE CONTRACTION; ANTAGONISTS AND INHIBITORS; DIABETIC NEPHROPATHIES; DRUG EFFECTS; PATHOPHYSIOLOGY;

BENZHYDRYL COMPOUNDS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; NEPHRONS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84996993010     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1608564     Document Type: Article

References (5)

1. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
2. Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiol Rev 2015;95:405-511.
3. Thurau KW, Dahlheim H, Grüner A, Mason J, Granger P. Activation of renin in the single juxtaglomerular apparatus by sodium chloride in the tubular fluid at the macula densa. Circ Res 1972;31:Suppl 2:182-6.
4. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015;66:255-70.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.